---
title: "Metformin and Severe Post-COVID-19 Outcomes Among Individuals with Diabetes Mellitus"
id: "medrxiv-9-metformin-and-severe-post-covid-19-outcomes-among-individuals-with-diabetes"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-9-metformin-and-severe-post-covid-19-outcomes-among-individuals-with-diabetes"
content_type: "clinical_feed_article"
specialty: "Research Highlights"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.07.06.26357398v1?rss=1"
published_at: "2026-07-09T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Metformin and Severe Post-COVID-19 Outcomes Among Individuals with Diabetes Mellitus
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-9-metformin-and-severe-post-covid-19-outcomes-among-individuals-with-diabetes
- **Specialty:** [Research Highlights](https://medichelpline.com/clinical-feed/research-highlights.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.07.06.26357398v1?rss=1)
- **Published At:** 2026-07-09T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
Background: Metformin is one of the most commonly prescribed medications for individuals with diabetes and may provide protection against long-term sequelae of COVID-19. Methods: We evaluated a retrospective cohort of individuals in the National Clinical Cohort Collaborative with type 2 diabetes mellitus and COVID-19 who were prescribed metformin or a dipeptidyl peptidase-4 inhibitor (DPP4i) at least 30 days before the onset of acute COVID-19 between October 1, 2021, and November 15, 2023. We compared the 12-month cumulative incidence of Long COVID diagnosis (ICD-10 U09.9: Post COVID-19 condition, unspecified), probable Long COVID (based on a model-derived phenotype), and mortality between individuals prescribed metformin vs. DPP4i. We applied Super Learner and targeted maximum likelihood estimation to obtain risk ratios while adjusting for covariates of interest. Results: In our sample of 53,332 individuals with type 2 diabetes and COVID-19, we found that metformin prescription was associated with a lower risk of all-cause mortality after COVID-19 (adjusted risk ratio [aRR] 0.61, 95% CI 0.51, 0.73).
## Clinical Analysis & Structured Key Points
medRxiv (Clinical Preprints) published a clinical update in Research Highlights on 09 Jul 2026. The item focuses on Metformin and Severe Post-COVID-19 Outcomes Among Individuals with Diabetes Mellitus. Review the original article for the full source wording and details.
## Related Clinical Research

- [GLP-1 Drugs May Help Reduce Lung Scarring After COVID](https://medichelpline.com/clinical-feed/medical-news-today-0-how-glp-1-drugs-like-ozempic-could-help-prevent-lung-scarring-after-covid.md)
- [Lactiplantibacillus plantarum LP28 Boosts NK Activity and Lowers Cold Incidence in Older Adults](https://medichelpline.com/clinical-feed/medrxiv-2-the-influence-of-long-term-supplementation-with-lactiplantibacillus-plantarum.md)
- [High-Fiber Diet Outperforms Metformin in Blood Sugar Control and Weight Loss](https://medichelpline.com/clinical-feed/medical-news-today-0-high-fiber-diet-vs-metformin-which-is-better-for-blood-sugar-control-weight-loss.md)
- [Vitamin B12 deficiency in long-term metformin use and clinician awareness: a scoping review](https://medichelpline.com/clinical-feed/bmj-open-10-vitamin-b12-deficiency-in-long-term-metformin-use-and-clinician-awareness-a-scoping-review.md)
- [Preconception, Gestational, and Postpartum Care for Type 2 Diabetes](https://medichelpline.com/clinical-feed/endocrine-news-0-preconception-gestational-and-postpartum-care.md)

## Navigation
- [← Back to Research Highlights Feed](https://medichelpline.com/clinical-feed/research-highlights.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.